ONYX Stock Overview
Develops, manufactures, and distributes generic and branded pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Onyx Biotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹56.75 |
| 52 Week High | ₹56.75 |
| 52 Week Low | ₹51.45 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONYX | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | n/a | 0.5% | 0.5% |
| 1Y | n/a | 42.5% | 27.5% |
Return vs Industry: Insufficient data to determine how ONYX performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ONYX performed against the Indian Market.
Price Volatility
| ONYX volatility | |
|---|---|
| ONYX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: ONYX's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: Insufficient data to determine ONYX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Harsh Mahajan | www.onyxbiotec.com |
Onyx Biotec Limited develops, manufactures, and distributes generic and branded pharmaceutical products in India. The company offers sterile water for injections; and acts as a pharmaceutical contract manufacturer for a range of dry powder injections and dry syrups. It also exports its products.
Onyx Biotec Limited Fundamentals Summary
| ONYX fundamental statistics | |
|---|---|
| Market cap | ₹1.03b |
| Earnings (TTM) | ₹30.32m |
| Revenue (TTM) | ₹537.49m |
33.9x
P/E Ratio1.9x
P/S RatioIs ONYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONYX income statement (TTM) | |
|---|---|
| Revenue | ₹537.49m |
| Cost of Revenue | ₹367.28m |
| Gross Profit | ₹170.21m |
| Other Expenses | ₹139.90m |
| Earnings | ₹30.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.67 |
| Gross Margin | 31.67% |
| Net Profit Margin | 5.64% |
| Debt/Equity Ratio | 123.7% |
How did ONYX perform over the long term?
See historical performance and comparison